CTT Pharma Expects Grant Decisions, Aims for Smoking Cessation Breakthrough

CTT Pharmaceutical Holdings, Inc. has announced that there are no delays in the processing of its NIH and NSF grants. These were submitted ahead of the January 6th deadline, with decisions anticipated by May or possibly April. The review of these grants is slated to commence in March.

The potential NIH grant would facilitate Johns Hopkins University in conducting clinical trials on CTT's innovative smoke-free, low-dose dissolvable strip. This product aims to become the first oral smoking cessation product released in 40 years.

CTT has expanded its team by adding two experienced personnel to assist with the grants. CEO Ryan Khouri emphasized the critical need to address the public health crisis posed by cigarette smoking, which claims over 8 million lives globally each year.